Clinical Distribution and Drug Resistance of Acinetobacter baumannii in a Hospital from 2019 to 2021
Download PDF

Keywords

Acinetobacter baumannii
Drug resistance
Drug sensitivity test

DOI

10.26689/jcnr.v7i3.4987

Submitted : 2023-04-30
Accepted : 2023-05-15
Published : 2023-05-30

Abstract

Objective: To analyze the clinical distribution and drug resistance of Acinetobacter baumannii (AB) and provide reference for the treatment of AB infection. Methods: AB isolated from clinical specimens of Huaihua First People’s Hospital from 2019 to 2021 were collected and identified by VITEK 2 Compact, an automated microbial identification and susceptibility testing system, in which drug sensitivity test was also performed. Excel was used for statistical analysis. Results: Among the 1,311 AB strains, 81.16% (1,064 strains) were from sputum samples, and the departments with the highest detections rates of AB were neurosurgery (24.33%), intensive care (15.48%) and infectious disease (11.44%). The drug sensitivity test showed that the resistance rate of 1,311 AB strains to compound sulfamethoxazole and amikacin was 28.38% and 20.54%, respectively, and the resistance rate to 10 other kinds of common antibiotics was more than 40%. Conclusion: The 1,311 AB strains isolated were widely distributed in clinical settings and had strong resistance to commonly used antibiotics. Therefore, it is necessary to strengthen the monitoring of pathogens and drug resistance, formulate reasonable and effective infection control measures, and ensure that antibiotics are used in a reasonable manner.

References

Mi X, Yang W, 2022, Clinical Distribution, Drug Resistance and Carbapenemase Gene Detection of Multidrug-Resistant Acinetobacter baumannii in a Hospital from 2013 to 2020. Journal of Guangdong Pharmaceutical University, 38(1): 37–42.

Jiao Y, Zhang S, Li H, et al., 2021, Distribution Characteristics and Drug Resistance of Acinetobacter baumannii in a Hospital. Chinese Journal of Disinfection, 38(1): 22–14.

Cassini A, Placeuras D, Eckmann T, et al., 2016, Burden of Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years Through a Population Prevalence-Based Modelling Study. PLoS Med, 13(10): e1002150.

Clinical and Laboratory Standards Institute, 2020, Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition.

Zheng Y, Bi X, Zhou J, et al., 2021, Analysis of Clinical Distribution and Drug Resistance of Acinetobacter baumannii in a Tertiary Hospital in 2020. Foreign Medical Antibiotics, 42(5): 290–293.

Liu Q, Wang K, Wang R, et al., 2021, Clinical Infection Characteristics and Drug Resistance of Multidrug-Resistant Acinetobacter baumannii in Beijing Haidian Hospital from 2018 to 2019. Modern Medicine and Clinic, 36(4): 828–832.

Xu N, Wang H, Zhou M, 2019, Risk Factors for Pan Drug Resistant Acinetobacter baumannii Colonization and Infection in Patients with Mechanical Ventilation. Chinese Journal of Disinfection, 36(6): 439–442.

Hu F, Guo Y, Zhu D, et al., 2020, Surveillance of Bacterial Resistance in Chinet Tertiary Hospital in 2019. Chinese Journal of Infection and Chemotherapy, 20(3): 233.

Lee C-R, Lee JH, Park M, et al., 2017, Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Front Cell Infect Microbiol, 7: 1.

Mekes AR, Zahlane K, Said LA, et al., 2020, The Clinical and Epidemiological Risk Factors of Infections Due to Multi-Drug Resistant Bacteria in an Adult Intensive Care Unit of University Hospital Center in Marrakesh-Morocco. J Infect Public Health, 13(4): 637–643.